FGFR3-TRACE (Tracking Mutations and Fusions in Urothelial Cancer): Use of anonymized patient samples for the establishment of newly developed assays for the detection of diagnostically relevant cancer biomarkers.

FGFR3-TRACE (Tracking Mutations and Fusions in Urothelial Cancer): Use of anonymized patient samples for the establishment of newly developed assays for the detection of diagnostically relevant cancer biomarkers. - FGFR3-TRACE (Tracking Mutations and Fusions in Urothelial Cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036842

Enrollment

Registered

2025-05-27

Start date

2025-07-21

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C68

Interventions

Group 1: Observational study (analytical laboratory study): Urine, blood, or tissue samples from patients with urothelial carcinoma are analyzed using digital PCR to detect the presence of FGFR3 alter

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Urothelial carcinoma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Aim: Rapid, valid, and highly sensitive results using a new methodology for potential therapeutic options for patients	—

Countries

Germany

Contacts

Public ContactHarald Bartsch

Gemeinschaftspraxis für Pathologie Traunstein

molpath@pathots.de+49 (0)8615250

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026